Related Experiment Video

Updated: Jul 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Editorial: Advancing precision therapies in glioblastoma

Theophilos Tzaridis1, Marike Broekman2, Konstantinos Gousias3,4,5

  • 1Cancer Genome and Epigenetics Program, NCI-Designated Cancer Center, Sanford Burnham, Prebys Medical Discovery Institute, La Jolla, CA, United States.

Frontiers in Oncology
|October 13, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
biomarkersblood-brain barrierdrug deliveryglioblastomatargeted therapytherapy

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.1K

Related Experiment Videos

Last Updated: Jul 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Ethical universality in medicine: A critical rational bioethics beyond cultural relativism.

Brain & spine·2026

NAMPT activation uncovers a senescence-specific vulnerability and promotes healthy aging in combination with NAM.

bioRxiv : the preprint server for biology·2026

Honeybadger, a micropeptide encoded by an alternative PVT1 transcript, is a critical negative regulator of RAS-MAPK signaling in MYC-driven tumors.

Genes & development·2026

CD155 regulates tumor growth and susceptibility to T cell mediated killing in diffuse midline glioma.

Neuro-oncology·2026

Immune cell imaging in the glioma microenvironment.

Brain research·2026

Ethical aspects of waiting lists in neurosurgery.

Acta neurochirurgica·2026

Metabolic dynamic score and machine learning: a novel approach to predicting pathological complete response in rectal cancer after neoadjuvant chemoradiotherapy.

Frontiers in oncology·2026

Association of alkalization therapy with long-term survival in stage IV or recurrent colorectal cancer: interaction with RAS mutation status.

Frontiers in oncology·2026

Study on the expression of p53, PTEN, and p16 in endometrial polyps of breast cancer patients receiving endocrine therapy: a comparative study of immunohistochemistry.

Frontiers in oncology·2026

Neoadjuvant therapy combined with immunotherapy for anal sphincter preservation rate, clinical efficacy, and safety in rectal cancer patients: a meta-analysis.

Frontiers in oncology·2026

Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study.

Frontiers in oncology·2026

Prevalence and clinical impact of PIK3CA and PTEN alterations from reflex genomic testing of newly diagnosed colorectal cancer: a population-based series.

Frontiers in oncology·2026

Myotonic dystrophy type 1 - updates on mechanisms of multisystemic manifestations, genetically targeted therapeutics, and preparing for a postapproval world.

Current opinion in neurology·2026

Immunotherapeutic efficacy of transdermal delivery of anti-CD3 antibody-conjugated magnetic nanoparticles using a hyaluronic acid-based dissolving microneedle patch.

Drug delivery and translational research·2026

Innovations in transcatheter interventions for hypoplastic left heart syndrome and borderline left heart structures from fetal to neonatal life: current evidence and systematic review of recent advances (2016-2025).

European journal of pediatrics·2026

Viewpoint on Multisensory Technologies.

Multisensory research·2026

CRISPR/Cas12a-based tag-free fluorescent biosensor using G-quadruplex specific thioflavin T for detection of oncogenic microRNAs.

Methods (San Diego, Calif.)·2026

HBVZ10 Exhibits Robust In Vivo Potency and Synergizes with Entecavir to Drive Efficient cccDNA Elimination and HBsAg Seroclearance.

Antiviral research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us